Pharma Pipelines Mixed as Moderna Flu Shot Wins FDA Panel

Pfizer ($PFE) dropped 7.3% following mixed oncology news this week. The company reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous non-small cell lung cancer failed to show a statistically significant overall survival benefit over docetaxel in the overall population. Offsetting the negative trial data, the FDA approved IBRANCE as a maintenance option for adults with HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy. The mixed results have reshaped $PFE's long-term pipeline narrative as investors weigh the lung cancer setback against the expanded IBRANCE indication.

Merck ($MRK) received an Outperform rating from CICC with a $138 price target. Bristol Myers Squibb ($BMY) is down 19% over the past year but has gained 8% over the past month. The broader healthcare sector gained 7.6% over the past six months, nearly mirroring the S&P 500 performance.

The FDA's Vaccines and Related Biological Products Advisory Committee unanimously backed Moderna ($MRNA)'s mRNA-based flu shot, mFlusiva, for adults 50 and older. Phase 3 data showed the vaccine to be approximately 27% more effective than a standard flu vaccine, positioning $MRNA's mRNA platform for a potential second major commercial use beyond COVID-19. This endorsement expands the company's role in routine respiratory vaccination for older adults and validates the broader applicability of its core technology platform.

AbbVie ($ABBV) announced its acquisition of Apogee Therapeutics, prompting Canaccord to raise its price target to $273 from $265 while reiterating a Buy rating. The firm updated its model following the transaction, stating that the Apogee deal strengthens $ABBV's long-term growth outlook. Separately, retail traders speculated on potential M&A activity following Novo Nordisk CEO comments that the company could afford a $20B, $30B or $40B deal if it was considered worthwhile, fueling buyout speculation in the obesity treatment space.

Johnson & Johnson ($JNJ) advanced cardiac ablation technology in Europe with the availability of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform. The Irvine, California-based company's expansion of this cardiac intervention technology strengthens its position in the European electrophysiology market. Intuitive Surgical ($ISRG) received acknowledgment for its da Vinci Single Port robotic platform, which Good Samaritan Hospital highlighted for enabling surgeons to perform complex procedures through a single small incision. The da Vinci Single Port system continues to expand the addressable market for minimally invasive robotic surgery beyond traditional multi-port approaches.

Abbott Laboratories ($ABT) is backed by bullish positioning from 73 hedge funds, with analyst expectations of 30.93% upside potential. The company has drawn mixed analyst signals recently, with one firm identifying hidden value in a potential breakup scenario while another trimmed its outlook on broader sector concerns. Eli Lilly ($LLY) expects to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027, according to Reuters, with plans to target the out-of-pocket market. Amgen ($AMGN) closed at $351.93, up 1.42% in the most recent trading session.

The Global Cell Therapy Human Raw Materials Market was valued at approximately $3.62 billion in 2025 and is expected to reach $4.21 billion in 2026, according to Healthcare Foresights. The market is projected to reach $18.94 billion by 2035, growing at a 16.3% CAGR between 2026 and 2035. Thermo Fisher Scientific ($TMO) was listed among key market players in the research report covering the cell therapy raw materials sector.